On November 9, 2022, 10x Genomics, Inc. (Nasdaq: TXG), a life sciences leader focused on mastering biology to advance human health, today announced the commercial availability of BEAM (Barcode-Enabled Antigen Mapping), a kitted solution for antibody and T-cell receptor (TCR) discovery. Built on top of 10x's industry-leading Chromium Single Cell Immune Profiling product, BEAM's proprietary antigen screening approach is fast and robust, delivering hundreds of antigen-receptor pairs with single cell gene expression. The combination of robust screening; simple, fast, and validated workflows; and, comprehensive interrogation of each cell has the potential to greatly accelerate and improve therapeutic discovery. "As nearly every disease involves the immune system in some way—whether it's an infectious disease, autoimmunity, cancer, or inflammation—it's critical to have a fundamental understanding of the immune response in order to fully understand the disease," said Ben Hindson, PhD, Co-Founder and Chief Scientific Officer of 10x Genomics. "BEAM enables researchers to gain more insight than ever into the immune system's basic mechanisms at high throughput and resolution, which can help translate the power of the natural immune response into the next wave of powerful, life-saving therapeutics."
10x Genomics Launches BEAM to Improve and Streamline Antibody and T-Cell Receptor Discovery; Barcode-Enabled Antigen Mapping (BEAM) Screens Multiple Antigens Against Thousands of B- or T-Cells to Identify Novel and Rare Antigen-Specific Repertoires
Login Or Register To Read Full Story